Compound
biphenyl
A benzenoid aromatic compound that consists of two benzene rings connected by a single covalent bond. Biphenyl occurs naturally in coal tar, crude oil, and natural gas. Formerly used as a fungicide for citrus crops.
Definition from ChEBI (CHEBI:17097), read 2026-09-23. CC BY 4.0.
Structure
Loading the model…
- Class
- Organic compound
- Formula
- C12H10
- Mass
- 154.212 g/mol
- Charge
- 0
- InChIKey
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N
- SMILES
- c1ccc(-c2ccccc2)cc1
- Look it up
- ChEBIPubChemBy InChIKey
Identity from ChEBI, geometry from PubChem. Not evidence.
Reactions
1 reaction
biphenyl+NADH(2-)+dioxygen+hydronCHEBI:32922+NAD(1-)
Reaction pageDirection not assertedBalance undeterminable
Rhea RHEA:18165CC BY 4.0Reference data
Registered, and not reported
- Source
- ClinicalTrials.gov
- Intervention
- biphenyl
- Status
- Completed, terminated or suspended
- Results posted
- No
Trials without posted results
587 trials
587 registered trials without posted results · Overdue (FDAAA 801): 106 · Showing 120 of 587
106 past the window14 within it, or no actual date
- NCT06483789suspended— Recruitment paused for Data Monitoring Committee (DMC) to review interim analysis data.expected 2027-01industry
- NCT05285813terminated— \<75% participation2026-05-15a university or hospital
- NCT05662228completed2026-05-05a university or hospital
- NCT07652567completed2026-04-30a university or hospital
- NCT07223671completed2026-02-19industry
- NCT06083571terminated— The eligibility criteria within the protocol led to the exclusion of a large proportion of potential participants, thereby limiting enrollment. During the conceptualization phase, the number of eligible patients was overestimated.2025-12-31a university or hospital
- NCT07235748completed2025-12-23industry
- NCT05807048completed2025-11-11a university or hospital
- NCT07604792suspended— Enrollment is suspended to address regulatory requirements. Follow-up of currently enrolled participants continues as planned.2025-11-07a university or hospital
- NCT05607017completed2025-10-07a university or hospital
- NCT05012631completed2025-10-03a university or hospital
- NCT07778472completed2025-09-18a university or hospitalpast the reporting window
Show the remaining 575
- NCT07435324completed2025-09-16industrypast the reporting window
- NCT03913559terminated— Closed due to slow accrual2025-09-15a university or hospitalpast the reporting window
- NCT03435939completed2025-09-03a university or hospitalpast the reporting window
- NCT02699645completed2025-08-27a university or hospitalpast the reporting window
- NCT04681105completed2025-08-05a university or hospitalpast the reporting window
- NCT03456817terminated— Slow patient accrual and appearance of a toxicity2025-05-31a university or hospitalpast the reporting window
- NCT06135493completed2025-03-30a university or hospitalpast the reporting window
- NCT02085265terminated— Lack of recruitment.2025-02-28a university or hospitalpast the reporting window
- NCT06823284completed2025-02-12industrypast the reporting window
- NCT06566794completed2025-01-10a university or hospitalpast the reporting window
- NCT06267586completed2024-12-30industrypast the reporting window
- NCT04106856completed2024-12-06a university or hospitalpast the reporting window
- NCT07435311completed2024-07-17industrypast the reporting window
- NCT05955885completed2024-07-01a university or hospitalpast the reporting window
- NCT05215236completed2024-05-31a university or hospitalpast the reporting window
- NCT06718062completed2024-05-01a university or hospitalpast the reporting window
- NCT04109885terminated— Insufficient recruitment.2024-01-30a university or hospitalpast the reporting window
- NCT06238154completed2024-01-12a university or hospitalpast the reporting window
- NCT05402397completed2023-12-31a university or hospitalpast the reporting window
- NCT06353958completed2023-12-31industrypast the reporting window
- NCT06063109completed2023-11-09industrypast the reporting window
- NCT04218539completed2023-11-05a university or hospitalpast the reporting window
- NCT05932277completed2023-09-13industrypast the reporting window
- NCT05852769completed2023-08-24industrypast the reporting window
- NCT04927299completed2023-08-15industrypast the reporting window
- NCT04580121completed2023-08-09industrypast the reporting window
- NCT01620788suspended— Substancial amendmentexpected 2023-07industry
- NCT05586477completed2023-06-23a university or hospitalpast the reporting window
- NCT05129761completed2023-06-01industrypast the reporting window
- NCT06299488completed2023-06-01industrypast the reporting window
- NCT06041178completed2023-05-25a university or hospitalpast the reporting window
- NCT03330028completed2023-04-18a university or hospitalpast the reporting window
- NCT02661035completed2023-04-17a university or hospitalpast the reporting window
- NCT05476354completed2023-04-03industrypast the reporting window
- NCT05512013completed2023-04-01US federal agencypast the reporting window
- NCT05155436completed2023-03-31a university or hospitalpast the reporting window
- NCT05475665completed2023-03-30industrypast the reporting window
- NCT06310642completed2023-03-13a university or hospitalpast the reporting window
- NCT05243199completed2023-03-01a university or hospitalpast the reporting window
- NCT06000137completed2023-01-14a university or hospitalpast the reporting window
- NCT05302388completed2023-01-09industrypast the reporting window
- NCT05663073completed2022-12-15industrypast the reporting window
- NCT05590936completed2022-12-07a university or hospitalpast the reporting window
- NCT05688098completed2022-11-24industrypast the reporting window
- NCT03324113completed2022-11-18industrypast the reporting window
- NCT05322889completed2022-10-04a university or hospitalpast the reporting window
- NCT05908903completed2022-08-07industrypast the reporting window
- NCT04736329completed2022-07-30a university or hospitalpast the reporting window
- NCT04765449completed2022-07-29a university or hospitalpast the reporting window
- NCT03082014terminated— completed for the primary study group of sporadic SVD patients, halted prematurely for the additional study group due to slow recruitment at 26 of 30 CADASIL patients in December 20222022-07-28a university or hospitalpast the reporting window
- NCT03666351completed2022-07-25industrypast the reporting window
- NCT04447235terminated— futility analysis has demonstrated no difference between arms2022-06-30a university or hospitalpast the reporting window
- NCT04350229completed2022-06-20a university or hospitalpast the reporting window
- NCT05713396completed2022-06-01a university or hospitalpast the reporting window
- NCT03186326completed2022-05-31a university or hospitalpast the reporting window
- NCT04504045terminated— Slow recruitment due to COVID-19, the study was stopped when recruited numbers fulfilled the pre-defined lower sample size.2022-05-10a university or hospitalpast the reporting window
- NCT04382352completed2022-04-26industrypast the reporting window
- NCT04715763terminated— Poor recruitment due to decrease in COVID-19 rates locally2022-04-26a university or hospitalpast the reporting window
- NCT04606563terminated— DSMC recommendation due to futility2022-04-22a university or hospitalpast the reporting window
- NCT03934307completed2022-04-20industrypast the reporting window
- NCT05254548completed2022-04-13industrypast the reporting window
- NCT04359953terminated— difficulty in recruiting2022-04-01a university or hospitalpast the reporting window
- NCT05828940completed2022-03-31a university or hospitalpast the reporting window
- NCT05226143completed2022-03-09industrypast the reporting window
- NCT02945813terminated— Trial was prematurely closed for accrual by the SAKK Board and the follow-up period shortened to one year after last RT fraction of the last patient2022-02-28a university or hospitalpast the reporting window
- NCT05182814completed2022-02-28industrypast the reporting window
- NCT04315467completed2022-02-10a university or hospitalpast the reporting window
- NCT01854814completed2022-02a university or hospitalpast the reporting window
- NCT05232370completed2022-01-06a university or hospitalpast the reporting window
- NCT04700007completed2021-12-31a university or hospitalpast the reporting window
- NCT02867800completed2021-12-30a university or hospitalpast the reporting window
- NCT04840641completed2021-12-17a university or hospitalpast the reporting window
- NCT04643691terminated— due to an Urgent Security Measure2021-12-07a university or hospitalpast the reporting window
- NCT02913664completed2021-11-30a university or hospitalpast the reporting window
- NCT04394117completed2021-11-14a university or hospitalpast the reporting window
- NCT03036904completed2021-11-11a university or hospitalpast the reporting window
- NCT04488978completed2021-11-09industrypast the reporting window
- NCT04466241completed2021-11-01a government bodypast the reporting window
- NCT05040880completed2021-10-31industrypast the reporting window
- NCT05392673completed2021-10-31a university or hospitalpast the reporting window
- NCT04356495completed2021-10-08a university or hospitalpast the reporting window
- NCT04238702completed2021-09-27a university or hospitalpast the reporting window
- NCT02240407completed2021-08-26a university or hospitalpast the reporting window
- NCT03779243completed2021-08-24a university or hospitalpast the reporting window
- NCT04330300suspended— Challenges with funding and very low incidence of COVID-19 at Irish study siteexpected 2021-07-31a university or hospital
- NCT05462535completed2021-07-15industrypast the reporting window
- NCT04328012terminated— difficult enrollment2021-07-01a university or hospitalpast the reporting window
- NCT04602845completed2021-06-30a university or hospitalpast the reporting window
- NCT04510662completed2021-05-15a government bodypast the reporting window
- NCT02769130suspended— Due to Health Canada losartan recall, a new formulation being added to the protocol/ temporary suspensionexpected 2021-05a university or hospital
- NCT04986384completed2021-04-07a university or hospitalpast the reporting window
- NCT03541408completed2021-04-01a university or hospitalpast the reporting window
- NCT03783754terminated— Not feasible to continue2021-03-21a university or hospitalpast the reporting window
- NCT04218552completed2021-02-25industrypast the reporting window
- NCT04354350completed2021-02-08a university or hospitalpast the reporting window
- NCT04354376completed2021-02-08a university or hospitalpast the reporting window
- NCT03785067terminated— Contractual and financial issues.2021-02-03a university or hospitalpast the reporting window
- NCT04158076completed2021-01-14industrypast the reporting window
- NCT04633967completed2020-12-30a research networkpast the reporting window
- NCT04643249completed2020-12-17industrypast the reporting window
- NCT03878524terminated— Low accrual2020-12-10a university or hospitalpast the reporting window
- NCT04467931completed2020-10-21a university or hospitalpast the reporting window
- NCT04349410completed2020-09-14a university or hospitalpast the reporting window
- NCT04505787completed2020-09-09a university or hospitalpast the reporting window
- NCT03267329completed2020-09-02industrypast the reporting window
- NCT04237090completed2020-08-28a university or hospitalpast the reporting window
- NCT03872232completed2020-08-12industrypast the reporting window
- NCT04094727completed2020-06-30a university or hospitalpast the reporting window
Papers screened
557 papers
- Compound
- biphenyl
- Screened
- 557
- Admitted
- 0
- Discarded
- 474
- Not read
- 83
- Showing
- 200 of 557
Discarded: the wrong intervention406 papers
- PMID:14740721cited by PMID:20384371; not about the subject it would be filed under2026-09-30
- PMID:14998742cited by PMID:20384371; not about the subject it would be filed under2026-09-30
- PMID:15074672cited by PMID:20384371; not about the subject it would be filed under2026-09-30
- PMID:15506185cited by PMID:20384371; not about the subject it would be filed under2026-09-30
- PMID:15763638cited by PMID:20384371; not about the subject it would be filed under2026-09-30
- PMID:15844204cited by PMID:20384371; not about the subject it would be filed under2026-09-30
- PMID:16289232cited by PMID:20384371; not about the subject it would be filed under2026-09-30
- PMID:16398111cited by PMID:20384371; not about the subject it would be filed under2026-09-30
- PMID:16472816cited by PMID:20384371; not about the subject it would be filed under2026-09-30
- PMID:16621064cited by PMID:20384371; not about the subject it would be filed under2026-09-30
- PMID:16764463cited by PMID:20384371; not about the subject it would be filed under2026-09-30
- PMID:16830530cited by PMID:20384371; not about the subject it would be filed under2026-09-30
and 394 more.
Discarded: another reason, stated per paper33 papers
- PMID:28083853no claim extracted — subject_absent — DOSED: 5-[4'-(substituted-methyl)[1,1'-biphenyl]-2-yl]-1H-tetrazoles (5a-g) and [2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl-substituted-1-carbodithioates (11h-q) | synthesized 5-[4'-(substituted-methyl)[1,1'-biphenyl]-2-yl]-1H-tetrazoles (5a-g) and [2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl-substituted-1-carbodithioates (11h-q), not biphenyl itself2026-09-29
- PMID:29247893no claim extracted — subject_absent — DOSED: garcinuntabiphenyls A-C (biphenyl derivatives), garcinuntins A-C, garcinuntine and thirteen known compounds isolated from Garcinia nuntasaenii roots | garcinuntins A-C, garcinuntabiphenyls A-C, garcinuntine and thirteen known compounds isolated from Garcinia nuntasaenii roots, not biphenyl itself2026-09-29
- PMID:31724863no claim extracted — subject_absent — DOSED: compound 15a, a biphenyl acid derivative APJ receptor agonist lead compound, described in the article text | compound 15a, a biphenyl acid derivative APJ receptor agonist (lead compound from a med-chem optimization series), not biphenyl itself2026-09-29
and 30 more.
Discarded: not retrievable30 papers
- PMID:21661886no PMID parsed, abstract under 200 characters, or no record returned by efetch2026-09-30
- PMID:22280280no PMID parsed, abstract under 200 characters, or no record returned by efetch2026-09-30
- PMID:6790389no PMID parsed, abstract under 200 characters, or no record returned by efetch2026-09-29
- PMID:38308073no PMID parsed, abstract under 200 characters, or no record returned by efetch2026-09-29
and 26 more.
Discarded: no extractable result4 papers
and 4 more.
Discarded: an endpoint this vocabulary does not hold1 paper
and 1 more.
Not read yet83 papers
- PMID:104640712026-09-29
- PMID:109223442026-09-29
- PMID:114805012026-09-29
- PMID:123999192026-09-29
- PMID:124189402026-09-29
- PMID:125474812026-09-29
- PMID:126008662026-09-29
- PMID:126411812026-09-29
- PMID:127275972026-09-29
- PMID:151215062026-09-29
- PMID:151956832026-09-29
- PMID:155333342026-09-29
and 71 more.
Measured, not recorded
- Compound
- biphenyl
- Endpoints measured
- 36 endpoints
- Recorded as a finding
- No
Show what was measured
reference values for blood PCB concentration
1.2-8.28 microg/L (males); 2.69-5.17 microg/L (females); overall range 0.9-56 microg/L
The PCBs RVs resulted between 1.2 e 8.28 microg/L for males and between 2.69 e 5.17 microg/L for females the general range varied from 0.9 to 56 microg/L.
PMID:15134393 · one of two readings recorded this
carcinogenicity and noncancer health hazards of oral biphenyl exposure (male rat urinary bladder tumors, female mouse liver tumors, kidney toxicity), narrative synthesis of experimental animal bioassays and mechanistic studies for EPA IRIS
increases
Not recorded as a finding: a review that discusses its trials without pooling them
The available health effects data for biphenyl provides suggestive evidence for carcinogenicity in humans, based on increased incidences of male rat urinary bladder tumors at high exposure levels and on female mouse liver tumors.
PMID:26529796 · one of two readings recorded this
Carcinogenicity (male rat urinary bladder tumors, female mouse liver tumors) and kidney toxicity from oral biphenyl exposure, reviewed across experimental animal bioassays and mechanistic studies
increases
Not recorded as a finding: a review that discusses its trials without pooling them
The available health effects data for biphenyl provides suggestive evidence for carcinogenicity in humans, based on increased incidences of male rat urinary bladder tumors at high exposure levels and on female mouse liver tumors.
PMID:26529796 · one of two readings recorded this
liver tumor incidence (hepatocellular adenoma/carcinoma), female BDF1 mice
increases
Exposure to biphenyl in the diet for 2 years was associated with a statistically significant dose-related increase in the incidence of liver tumors (hepatocellular adenomas or carcinomas) in female BDF1 mice (Table 3).
PMID:26529796 · one of two readings recorded this
renal toxicity (mineralization, necrosis, hyperplasia)
increases
Kidney toxicity is also a potential human health hazard of biphenyl exposure.
PMID:26529796 · one of two readings recorded this
urinary bladder tumor incidence (transitional cell papilloma/carcinoma), male F344 rats
increases, 31/50 papilloma or carcinoma combined at high dose vs 0/50 controls, n = 50
A dose-related increase in transitional cell papilloma and carcinoma of the urinary bladder was reported in male F344 rats exposed to biphenyl in the diet for 2 years (Table 2).
PMID:26529796 · one of two readings recorded this
breast cancer risk, Group II and Group III PCB congeners
increases, OR = 1.23 (95% CI 1.08-1.40) for Group II; OR = 1.25 (95% CI 1.09-1.43) for Group III
The pooled ORs were 1.23 (95%CI: 1.08–1.40) for group II and 1.25 (95%CI: 1.09–1.43) for group III, respectively.
PMID:26555153 · one of two readings recorded this
breast cancer risk, total PCB exposure (highest vs lowest category)
no effect, OR = 1.09 (95% CI: 0.97-1.22)
Overall, the summary OR of total PCBs was slightly elevated but not statistically significant and heterogeneity was relatively high (OR = 1.09, 95%CI: 0.97–1.22, I2 = 55.4%).
PMID:26555153 · one of two readings recorded this
anti-fungal activity
increases, Some of the compounds have shown significant pharmacological properties.
Some of the compounds have shown significant pharmacological properties.
PMID:28083853 · both readings recorded this
anti-HIV-1 reverse transcriptase inhibition activity
Anti-HIV activity using anti-HIV-1 reverse transcriptase and syncytium inhibition assays, and cytotoxic activity against a panel of cultured mammalian cancer cell lines of isolated compounds were investigated.
PMID:29247893 · one of two readings recorded this
cytotoxic activity against cultured mammalian cancer cell lines
Anti-HIV activity using anti-HIV-1 reverse transcriptase and syncytium inhibition assays, and cytotoxic activity against a panel of cultured mammalian cancer cell lines of isolated compounds were investigated.
PMID:29247893 · one of two readings recorded this
urinary estrone-3-glucuronide, pregnanediol-3-glucuronide and FSH levels across the menstrual cycle
decreases, n = 70
We observed that high (>3.0 parts per billion [ppb]) and medium (>1.0-3.0 ppb) PBB exposure were associated with lower E13G levels across the menstrual cycle and lower FSH levels during the follicular phase, compared with low PBB exposure (≤1.0 ppb).
PMID:31180930 · one of two readings recorded this
urinary reproductive hormone levels (estrone-3-glucuronide, pregnanediol-3-glucuronide, FSH) across the menstrual cycle
decreases, n = 70
Not recorded as a finding: the trial gave a chemically different species
We observed that high (>3.0 parts per billion [ppb]) and medium (>1.0-3.0 ppb) PBB exposure were associated with lower E13G levels across the menstrual cycle and lower FSH levels during the follicular phase, compared with low PBB exposure (≤1.0 ppb).
PMID:31180930 · one of two readings recorded this
Association between polychlorinated biphenyl exposure and breast cancer risk, reviewed across epidemiologic studies
no effect
Not recorded as a finding: the trial gave a chemically different species
However, the results of most epidemiologic studies do not support an association between PCB exposure and breast cancer risk.
PMID:31521536 · one of two readings recorded this
offspring birthweight (lowest quartile) and gestational age by paternal PBB/PCB tertile
increases, aRR = 2.06 (95% CI: 1.12, 3.79), upper paternal PBB tertile vs lower tertile, n = 336
Not recorded as a finding: the trial gave a chemically different species
Lowest quartile offspring birthweight was associated with monotonic increased adjusted risk ratios (aRR) in the middle (aRR=1.67, 95% CI: 0.93, 2.99) and upper tertiles (aRR=2.06, 95% CI = 1.12, 3.79) for PBB (Table 3).
PMID:36041536 · one of two readings recorded this
offspring birthweight, lowest quartile
increases, aRR = 1.67 (95% CI: 0.93, 2.99) middle tertile; aRR = 2.06 (95% CI: 1.12, 3.79) upper tertile, paternal PBB, n = 336
Lowest quartile offspring birthweight was associated with monotonic increased adjusted risk ratios (aRR) in the middle (aRR=1.67, 95% CI: 0.93, 2.99) and upper tertiles (aRR=2.06, 95% CI = 1.12, 3.79) for PBB (Table 3).
PMID:36041536 · one of two readings recorded this
offspring preterm birth / gestational age
no effect
Preterm gestational age was not associated with increasing paternal PBB or PCB levels in the log-risk models (Table 4).
PMID:36041536 · one of two readings recorded this
NLRP3 inflammasome inhibition (binding affinity, IC50) and anti-inflammatory activity in a mouse acute peritonitis model
decreases, IC50 = 0.57 μM; KD = 1.15 μM
Not recorded as a finding: the trial gave a chemically different species
The representative compound H28 was identified as potent and specific NLRP3 inflammasome inhibitor with IC50 values of 0.57 μM.
PMID:38492493 · one of two readings recorded this
NLRP3 inflammasome pathway activation, mouse acute peritonitis model
decreases
The results in a mouse acute peritonitis model revealed that H28 effectively inhibit the NLRP3 inflammasome pathway, demonstrating their anti-inflammatory properties.
PMID:38492493 · one of two readings recorded this
NLRP3 protein binding (KD) and inflammasome assembly/activation inhibition by biphenyl-sulfonamide compound H28, in vitro and in a mouse acute peritonitis model
decreases
Not recorded as a finding: the trial gave a chemically different species
Preliminary mechanistic studies have revealed that compound H28 exhibits direct binding to the NLRP3 protein (KD: 1.15 μM), effectively inhibiting the assembly and activation of the NLRP3 inflammasome.
PMID:38492493 · one of two readings recorded this
diabetes mellitus
increases, OR = 3.593 (95% CI 2.566, 5.031)
The pooled OR showed that PCB congener exposure among the population was highly associated with the risk of DM (OR = 3.593, 95% CI 2.566, 5.031).
PMID:39095444 · one of two readings recorded this
hypertension
no effect, OR = 1.335 (95% CI 0.902, 1.976)
However, the pooled OR showed a lack of association between PCB congener exposure and the risk of HTN (OR = 1.335, 95% CI 0.902, 1.976).
PMID:39095444 · one of two readings recorded this
hypertriglyceridaemia
no effect, OR = 1.611 (95% CI 0.981, 2.643)
The pooled OR was 1.611 (95% CI 0.981, 2.643), suggesting no association between PCB congener exposure and the risk of HTG.
PMID:39095444 · one of two readings recorded this
low HDL cholesterol
decreases, OR = 0.34 (95% CI 0.092, 1.258)
However, the pooled OR (0.34, 95% CI 0.092, 1.258) showed that there was a negative association between PCB congener exposure and the risk of having low HDL.
PMID:39095444 · one of two readings recorded this
metabolic syndrome, dioxin exposure
increases, OR = 2.742 (95% CI 1.936, 3.883)
The pooled OR described minimal association (OR = 2.742, 95% CI 1.936, 3.883).
PMID:39095444 · one of two readings recorded this
metabolic syndrome, PCB exposure
no effect, OR = 1.162 (95% CI 0.994, 1.357)
The pooled OR showed a limited association (OR = 1.162, 95% CI 0.994, 1.357) that was statistically insignificant (P > 0.05).
PMID:39095444 · one of two readings recorded this
obesity (BMI > 30 kg/m2)
no effect, OR = 1.875 (95% CI 0.883, 3.979)
The pooled effects estimated from all three studies showed no statistical significance (P = 0.102, random effect) between the association of PCB congener exposure and an increase in BMI.
PMID:39095444 · one of two readings recorded this
Ectopic lesion growth in a mouse endometriosis model and ERβ-mediated epigenetic regulation following PCB-126 exposure
increases
Not recorded as a finding: the trial gave a chemically different species
In a mouse model of endometriosis, PCB-126 exposure significantly promoted the growth of ectopic lesions by activating the Steroid Receptor Coactivator-1 (SRC-1) isoform/Matrix Metalloproteinase-9 (MMP9)/Estrogen Receptor-β (ERβ) axis, a critical pathway driving disease progression.
PMID:40951281 · one of two readings recorded this
endometriotic ectopic lesion volume and ERβ/AXL/GAS6/DNMT3A pathway activation in mouse and human endometriotic tissue
increases
Not recorded as a finding: the trial gave a chemically different species
Compared to vehicle-treated mice, PCB126 exposure significantly increased the volume of ectopic lesions.
PMID:40951281 · one of two readings recorded this
endometriotic ectopic lesion volume, AXL inhibitor effect
decreases
BMS-777607 treatment significantly reduced the volume of endometriotic lesions in PCB126-exposed mice compared to the vehicle-treated group (and).
PMID:40951281 · one of two readings recorded this
endometriotic ectopic lesion volume
increases
Compared to vehicle-treated mice, PCB126 exposure significantly increased the volume of ectopic lesions.
PMID:40951281 · one of two readings recorded this
Inhibition of LPS-induced nitric oxide release in BV2 microglial cells by six new biphenyl derivatives isolated from Garcinia yunnanensis
decreases
Not recorded as a finding: the trial gave a chemically different species
Additionally, all six new compounds were evaluated for their ability to inhibit LPS-induced nitric oxide (NO) release in BV2 microglial cells, demonstrating moderate anti-inflammatory activity.
PMID:42055094 · one of two readings recorded this
LPS-induced nitric oxide release in BV2 microglial cells
decreases
Additionally, all six new compounds were evaluated for their ability to inhibit LPS-induced nitric oxide (NO) release in BV2 microglial cells, demonstrating moderate anti-inflammatory activity.
PMID:42055094 · one of two readings recorded this
LPS-induced nitric oxide release inhibition in BV2 microglial cells
decreases
Not recorded as a finding: the trial gave a chemically different species
Additionally, all six new compounds were evaluated for their ability to inhibit LPS-induced nitric oxide (NO) release in BV2 microglial cells, demonstrating moderate anti-inflammatory activity.
PMID:42055094 · one of two readings recorded this
blood/tissue PCB congener concentration after known exposure incidents vs general-population controls
increases, 6.9 ppb (Yusho patients) vs 1.6 ppb (Fukuoka controls), n = 11
Figure 1 graphically depicts mean PCB serum levels for the selected tetra through heptachlorinated PCBs in blood of 11 patients as compared to the control blood from the general population.
PMID:8187704 · one of two readings recorded this
blood/tissue PCB congener concentrations in exposed cohorts (Yusho patients, Guam workers, firefighters, exposed children, Vietnam veterans) versus controls
increases, 6.9 ppb (Yusho patients) vs 1.6 ppb (Fukuoka controls), n = 11
Not recorded as a finding: the trial gave a chemically different species
Figure 1 graphically depicts mean PCB serum levels for the selected tetra through heptachlorinated PCBs in blood of 11 patients as compared to the control blood from the general population.
PMID:8187704 · one of two readings recorded this
Other names
4 names
Resolves to: biphenyl
- Also called
- 1,1'-Biphenyl1,1'-DiphenylE230Phenylbenzene